BlackThorn Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.blackthornrx.com
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
- Conditions
- Motor DisorderParkinson Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03608371
- Locations
- 🇺🇸
BlackThorn Investigator Site, Dallas, Texas, United States
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo oral capsule(s)
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT03193398
- Locations
- 🇺🇸
United States, Memphis, Tennessee, United States
🇺🇸United States, Florida, Orlando, Florida, United States
A Study of LY2940094 in Participants With Alcohol Dependency
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT01798303
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT01724112
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01404091
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada
A Study of LY2940094 in Major Depressive Disorder
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT01263236
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada